Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient

Autoimmune Encephalitis Clinical Trial

— CarMa2  

Official title:

Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05645185
• Other study ID #: 820
• Status: Completed
• Start date: October 1, 2021
• Est. completion date: October 1, 2022

Study information

• Verified date: December 2022
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Paraneoplastic neurological syndromes (PNS) are rare complications of cancer occurring in 0.01% of cases. Their clinical, biological and radiological presentation is heterogeneous and may constitute a diagnostic challenge. Anti-Ma2 PNS are rare diseases with a guarded prognosis. They are most often associated with a seminoma-like testicular tumor but can also be associated with lung cancer. Classically, they present as limbic, diencephalic and/or brainstem encephalitis. Anti-Ma2 antibodies target intracellular receptors and are characteristic of a particular form of encephalitis. Atypical manifestations including narcolepsy-cataplexy, weight gain, sexual dysfunction and motor neuron syndrome have been described and explain the difficulty in diagnosing anti-Ma2 associated PNS. It seems interesting to better characterize the phenotypes of Ma2 patients in order to optimize the diagnosis and follow-up.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: October 1, 2022
• Est. primary completion date: March 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Neurological disorder
• Anti-Ma2 positivity in sera or CSF
• Patient > 18 years old

Exclusion Criteria:

• Patient without clinical data
• Patient without Ma2 antibody in sera or CSF

Related Conditions & MeSH terms

• Autoimmune Encephalitis
• Encephalitis
• Paraneoplastic Syndromes

Intervention

Diagnostic Test:
• Diagnosis test
Tests can be used: immunofluorescence, immunodot, western blot, tests CBA on sera or CSF.

Locations

Country	Name	City	State
France	Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rankin score	Follow up and survival (rankin score)	12 month after diagnosis